
Centre caps cancer medicine trade margins at 30% of MRP
The story in brief
The Centre capped trade margins on cancer medicines at 30% of the Maximum Retail Price (MRP) to address excessive markups and improve affordability. The impact on retail prices will depend on implementation and the medicines covered under the revised pricing framework.